Interim Results of Randomized Comparison of Ponatinib Starting Doses in Chronic-Phase CML
Response-based ponatinib dosing demonstrated clinical benefit in patients with resistant chronic-phase chronic myeloid leukemia (CML) with rate of arterial occlusive (AO) events that did...
Lenzilumab Demonstrates Clinical Benefit in Patients With Chronic Myelomonocytic Leukemia
A phase I study found that lenzilumab, an engineered human IgG1K monoclonal antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), was associated with a clinical...
International Prognostic Score Predicts Time to First Treatment in Patients With Early-Stage CLL
An international prognostic score (IPS-E) consisting of a sum score for three markers for consistently predicted time to first treatment (TTFT) in patients with...
BTKi Improves Disease Control in CLL After Progression on Venetoclax
Treatment with a Bruton tyrosine kinase inhibitor (BTKi) showed efficacy in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) that progressed on venetoclax, according to...
Demystifying PCR-Based Molecular Monitoring in CML
When imatinib, the first tyrosine kinase inhibitor (TKI), was approved for the treatment of chronic myeloid leukemia (CML) in 2001, the disease’s natural history...
Study Examines Trends in Real-World Treatment Sequencing Patterns for CLL/SLL
The availability of B-cell receptor inhibitors (BCRis) and other novel agents for the treatment of chronic lymphocytic leukemia (CLL) has reshaped the treatment paradigm...
Outcomes With Idelalisib Differ in the Clinical Trial Versus Real-World Setting
According to a real-world analysis published in JAMA Oncology, treatment outcomes with idelalisib differed between patients with follicular lymphoma (FL) and chronic lymphocytic leukemia...
Zanubrutinib Active in Patients with Treatment-Naive Del17p CLL/SLL
Approximately 93% of patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and del17p responded to treatment with the next-generation Bruton tyrosine kinase (BTK)...
Is Chemoimmunotherapy for Upfront CLL on Life Support?
For years, standard of care first-line treatment for chronic lymphocytic leukemia (CLL) included the FCR (fludarabine, cyclophosphamide, rituximab) chemoimmunotherapy regimen. However, the past decade...
Acalabrutinib Treatment Superior to Obinutuzumab Plus Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia
Acalabrutinib, alone or combined with obinutuzumab, led to greater improvements in progression-free survival (PFS), compared with obinutuzumab plus chlorambucil, in patients with treatment-naïve chronic...
Current Issue
July 2021 Bonus Mid-Year Edition, Volume 7 Issue 9
This issue features conversations with ASH Clinical Research Training Institute graduates, highlights from the virtual ASCO and EHA annual meetings, and more.